Exploring the secretion of immunogenic gluten peptides in breast milk from celiac and non celiac mothers

Ángela Ruiz-Carnicer^{1,†}, Verónica Segura^{1,†}, María de Lourdes Moreno¹, Cristóbal Coronel Rodríguez², Carolina Sousa¹, and Isabel Comino^{1,*}

- ¹Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, 41012
 Seville, Spain.
- 7 ²Health Center Amante Laffón, Seville, Spain.
- 8 [†]These authors contributed equally to this work and share first authorship.
- 9 * Correspondence:
- 10 Isabel Comino
- 11 icomino@us.es
- Keywords: antigens, breast milk; celiac disease; gluten exposure; gluten-free diet; gluten
 immunogenic peptides.
- 14
- 15 Abstract
- 16 Background: Exposure to antigens is crucial for child immune system development, aiding disease
- 17 prevention and promoting infant health. Some common food antigen proteins are found in human
- 18 breast milk. However, it is unclear whether gluten antigens linked to celiac disease (CD) are transmitted
- 19 through breast milk, potentially impacting the development of the infant's immune system.
- 20 **Objective:** This study aimed to analyze the passage of gluten immunogenic peptides (GIP) into human
- 21 breast milk. We evaluated the dynamics of GIP secretion after lactating mothers adopted a controlled
- 22 gluten-rich diet.
- Methods: We prospectively enrolled 96 non-CD and 23 CD lactating mothers, assessing total proteins and casein in breast milk, and GIP levels in breast milk and urine. Subsequently, a longitudinal study was conducted in a subgroup of 12 non-CD lactating mothers who adopted a controlled gluten-rich diet. GIP levels in breast milk and urine samples were assayed by multiple sample collections over 96 hours.

28 **Results:** Analysis of a single sample revealed that 24% of non-CD lactating mothers on a regular 29 unrestricted diet tested positive for GIP in breast milk, and 90% tested positive in urine, with 30 significantly lower concentrations in breast milk. Nevertheless, on a controlled gluten-rich diet and the 31 collection of multiple samples, GIP were detected in 75% and 100% of non-CD participants in breast 32 milk and urine, respectively. The transfer dynamics in breast milk samples were long-enduring and 33 GIP secretion persisted from 0 to 72 h. In contrast, GIP secretion in urine samples was limited to the 34 first 24 h, with inter-individual variations. In the cohort of CD mothers, 82.6% and 87% tested negative 35 for GIP in breast milk and urine, respectively.

36 **Conclusions:** This study definitively established the presence of GIP in breast milk, with substantial 37 inter-individual variations in secretion dynamics. Our findings provide insights into distinct GIP 38 kinetics observed in sequentially collected breast milk and urine samples, suggesting differential gluten 39 metabolism patterns depending on the organ or system involved. Future research is essential to 40 understand whether GIP functions as sensitizing or tolerogenic agents in the immune system of 41 breastfed infants.

42 Introduction

Celiac disease (CD) is a systemic disorders triggered by exposure to dietary gluten in genetically predisposed individuals [1,2]. It is a common disease that can affect individuals of all ages and is characterized by a wide spectrum of clinical manifestations. The symptoms include abdominal pain, bloating, nausea, vomiting, and/or diarrhea. Additionally, extra-intestinal manifestations can occur, such as blistering skin rashes, ataxia, bone disease, and issues in the reproductive and endocrine systems, among others [3].

49 The diagnostic rate for this pathology has increased over the last 10 years [4]. Worldwide 50 epidemiological data show that CD is ubiquitous, with a prevalence of 1.4% [5], and is higher in

51 females than in males [4-8]. The increase in this prevalence may, in part, be attributed to improved 52 recognition and testing of the disease. However, there may also be a real increase in the incidence of 53 this immune disorder, related to environmental factors that promote a loss of tolerance to dietary gluten 54 [9]. Breastfeeding and the timing of gluten introduction have been particularly considered influential 55 factors [10]. Nevertheless, the available evidence regarding the relationship between CD and breast 56 milk remains inconclusive. Extended breastfeeding and, notably, breastfeeding at the time of gluten 57 introduction seem to decrease the risk of developing CD or at least postpone its onset [11,12]. However, 58 conflicting findings persist, as some studies have been unable to establish breastfeeding as protective 59 against the development of CD [13-15].

60 Breastfeeding significantly influences the composition of the intestinal microbiota in the infant 61 and offers substantial potential to prevent allergic diseases [16,17]. The study of breast milk 62 composition is crucial not only for understanding the nutritional requirements of infants, but also for 63 evaluating its impact on neurodevelopment, immune system maturation, and gut development, among 64 others [18]. Additionally, breastfeeding plays a dual role in promoting tolerance through the presence 65 of immunomodulatory substances and facilitating antigen transfer. The presence of food antigens in 66 breast milk is a significant source of early oral exposure that is critical for establishing and reinforcing 67 oral tolerance [19].

68 Common food antigens found in human breast milk include proteins derived from egg 69 (ovalbumin) [20], cow milk (casein and beta-lactoglobulin) [21], and peanuts (arah h1 and arah h2) 70 [22,23]. The frequency and concentration of these dietary proteins in breast milk vary widely among 71 women, with approximately 50% excreting them at concentrations ranging from 0.1 to over 1000 ng/ml 72 [24-26]. However, the presence of certain proteins/peptides including gluten remains unclear [27,28]. 73 Gluten proteins have unique properties compared to other dietary proteins. In particular, they contain 74 high proportions of glutamine and proline residues, making them resistant to degradation by

gastrointestinal proteases. Consequently, relatively long gluten peptides with intact immunotoxic epitopes accumulate in the lumen of the small intestine and cross the epithelial barrier, ultimately entering the systemic circulation [29-31]. This raises the possibility of their subsequent secretion through the mammary glands into breast milk. Therefore, the possible presence of gluten peptides in breast milk could promote oral tolerance or sensitivity to gluten in breastfed infants.

80 Our research group is a pioneer in identifying and analyzing gluten in human samples. In 81 particular, monoclonal antibodies (moAbs) have been used to develop immunoassays for the sensitive 82 and specific detection of the gluten immunogenic peptides (GIP). These assays have enabled to 83 measure GIP concentrations in human samples, including feces and urine, confirming their absorption 84 into the bloodstream [32-36]. Given their resistance to gastrointestinal digestion, GIP play a key role 85 in triggering immunogenic responses within T cells of individuals diagnosed with CD. However, to 86 date, there have been no studies that confirm the existence of gluten peptides in breast milk and if they 87 are immunogenic. On this basis, the aim of this study is to understand the transfer and secretion 88 dynamics of GIP in breast milk. Initially, we carried out a cross-sectional study to analyze the GIP in 89 breast milk samples within a cohort of mothers with and without CD and assessed total protein and caseins secretion. Secondly, we conducted an exploratory longitudinal clinical study to elucidate the 90 91 differential kinetics of GIP secretion in human milk and urine by examining non-CD mothers after a 92 controlled gluten-rich diet.

93

94 Materials and methods

95

96 Study design and participants

97 Cross-sectional study

This cross-sectional study was conducted between September 2020 and September 2023, and included lactating mothers with and without CD. Potential volunteers were invited to participate via the following official notification: Centro de Salud Amante Laffón (Sevilla, Spain), Federación de Asociaciones de Celíacos de España (FACE), Asociación Provincial de Celíacos de Sevilla (Asprocese) and social networks (https://celiacos.org/la-universidad-de-sevilla-estudia-la-presenciade-peptidos-del-gluten-en-la-leche-materna/).

104 A questionnaire was administered to assess the gestational age of the children at delivery and 105 during sample collection process. Furthermore, mothers with CD were asked about the date of CD 106 diagnosis, results of the last duodenal biopsy study, and serum CD antibodies. The inclusion criteria 107 for the cohort of non-CD mothers were as follows: (1) over 18 years of age; (2) regular gluten 108 consumption; and (3) no prior diagnosis of CD, non-CD gluten sensitivity, food allergies, food 109 intolerances, or other gastrointestinal diseases. The inclusion criteria for the cohort of mothers with 110 CD were as follows: (1) over 18 years of age; (2) breastfeeding mothers previously diagnosed with 111 CD, and (3) all volunteers had followed a gluten-free diet (GFD) for at least 2 years prior to enrolling 112 in the study. The exclusion criteria were as follows: (1) participants with associated pathologies or 113 severe psychiatric diseases; and (2) participants who did not collect the samples properly.

This study was conducted in accordance with the principles of the Declaration of Helsinki. The
study protocol was approved by the regional research ethics committee (ID/Numbers: 0364-N-20,
Comunidad Autónoma de Andalucía, Spain), and written informed consent was obtained from all
participants.

Detailed instructions were provided to all participants at the beginning of the study. Breast milk and urine samples were consecutively collected from each participant. The parameters analyzed were total protein, casein and GIP level in breast milk, and GIP level in urine.

121

122 Longitudinal study

123	A longitudinal study was conducted in a selected subgroup of non-CD mothers who were
124	instructed to complete a two-phase study: (1) an initial 3-day phase with a controlled gluten-rich diet
125	and (2) a second 5-day phase with a strict GFD. During this study, participants were provided with a
126	menu planning with foods rich in gluten (pizza, sandwich, wheat pancakes, pasta, croutons, lasagna,
127	etc.) for the first period, and menus with gluten-free (unprocessed or minimally processed) foods for
128	the second phase (Figure 1). All volunteers collected consecutive urine and milk samples at 0 h during
129	the controlled gluten-rich diet and at 3, 6, 24, 48, 72, and 96 h after the start of the GFD.

130

131 Milk and urine collection

132 The participants were instructed to collect 10 mL of mature milk and 5 mL of urine in a sealed 133 sterile container. Mothers expressed the milk samples manually or by pump and immediately froze the 134 milk and urine sample at -20 °C until collected by the researchers. Once in the laboratory, the samples 135 were homogenized, and after aliquoting, they were stored at -20 °C. To optimize the milk protocol, 136 the following were used: 1) whole breast milk samples, and 2) whey samples obtained by centrifuging 137 an aliquot of the milk sample for 5 min at 8000 x g (removal of fat content and cellular elements that 138 could interfere with immunoassays). To ensure temporal coherence and minimize potential data 139 variations, milk and urine samples were collected consecutively over time.

140

141 **Total protein concentration**

The protein concentration in the whole milk and whey was quantified using a Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific Inc. Waltham, Massachusetts, USA) adapted to
microplates. Briefly, 25 μL of milk/whey or standard diluted was added to 96-well plates in duplicate.
After covering the plates and incubating at 37°C for 30 minutes, optical densities were read at 562 nm
in the Multiskan Sky Reader (Thermo Fisher Scientific Inc. Waltham, Massachusetts, USA). Each
sample was participants to duplicate analyses on different dates.

148

149 Casein concentration

150 The case on concentration in breast milk samples was measured by sandwich-type enzyme-151 linked immunosorbent assay (ELISA) using the AlerTox ELISA Casein Kits (AlerTox ELISA, 152 Hygiena Diagnostic España S.L., Seville, Spain), following the manufacturer's guidelines with minor 153 modifications. Briefly, breast milk samples were incubated for 15 min at 60°C with gentle agitation in 154 extraction buffer and centrifuged. ELISA was performed using a microtiter plate and standards 155 previously diluted 1:100. The samples were then incubated with a casein-conjugated antibody for 20 156 min. The TMB case in substrate solution was then added. Colour development was stopped with a stop 157 solution of casein, and absorbance at 450 nm was measured using a Multiskan Sky Reader microplate 158 reader (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA). A minimum of two separate 159 aliquots from each sample were examined on different days.

160

161 **Determination of GIP in milk and urine samples**

162 Milk and urine samples were processed according to the guidelines provided by the 163 manufacturer (iVYCHECK GIP Urine based on G12 and A1 moAbs; Biomedal S.L., Seville, Spain).

164	Subsequently, 100 μ L of each sample was applied to the detection test strip. After a 30-minute
165	incubation period, the immunochromatographic strip was assessed using a lateral flow test reader
166	cassette. The limit of detection (LoD) was established through visual examination (2.25 ng GIP /mL),
167	and the measuring range was 3.12-25 ng GIP /mL that was determined using the iVYCHECK Reader
168	(Biomedal S.L.). Each sample was run in duplicate, and at least two different aliquots of each sample
169	were tested on different days.
170	
171	Statistical Analysis
172	The results of the quantitative variables were expressed using the median and interquartile
173	range (IQR), and those of the qualitative variables were expressed as percentages. The goodness-of-fit
174	to normality was calculated using the Shapiro-Wilk test.
175	The Mann–Whitney U test was used to compare quantitative variables in independent groups,
176	and the Wilcoxon signed-rank test was used to compare quantitative variables in dependent groups.
177	The McNemar test was used to compare qualitative variables within dependent groups. For all the
178	cases, $P < 0.05$ was considered statistically significant. The data analysis was performed using SPSS
179	26.0 software for Windows (SPSS Inc.).
180	
181	Results
182	
183	Participants
184	We recruited 96 non-CD lactating mothers taking a normal unrestricted diet with a median age
185	of 35 (IQR: 32-37) and 23 CD lactating mothers under long-term GFD with a median age of 35 (IQR:

186 31-37). In non-CD mothers, the mode of delivery of the fetus was: 81% (78/96) vaginal and, 17%
(16/96) cesarean. For CD mothers, the mode of delivery of the fetus was: 17% (4/23) vaginal and, 4%
(1/23) cesarean. The gestational age, 40 (IQR: 39-40) weeks, was similar in both cohorts. However,
the median of the baby's age was 2 (IQR:1-5) months in non-CD mothers and 8 (IQR: 4-20) months
in CD-mothers.

191

192 Cross-sectional study

As this was a non-interventional study, and neither the amount of fluid ingested, nor the feeding pattern of the lactating mothers was modified. Additionally, urine and breast milk samples were collected only once.

196 Determination of total protein and casein in breast milk

To evaluate whether differences in the diets of non-CD and CD mothers could affect the protein content of their breast milk, we analyzed protein concentrations before and after whey separation. The protein concentration was higher in whole milk than in whey in both cohorts (Wilcoxon test, P<0.001) (Figure 2A). In CD mothers, the median was 9.7 (IQR= 9.1-12.8) and 9 mg/mL (IQR =8-11) for whole breast milk and whey samples, respectively, while in non-CD mothers was 10.7 (IQR= 9.7-12) and 9.8 mg/mL (IQR=8.6-11.6). Protein levels values were similar between the study cohorts, with no significant differences (Mann–Whitney U test, P=0.273).

Bovine casein is one of the non-human proteins most frequently found in human breast milk [21,37,38]. In this study, casein was detected in 78.15% of the samples (93/119) (Figure 2B), specifically 65% (16/23) in the cohort of CD mothers and 79% (76/96) in non-CD mothers (median 62.5 ng/mL; IQR 50–76 and median 60.7 ng/mL; IQR 52.2–73.4, respectively). As expected, the

results showed no significant differences between the bovine casein values of the control and CD
mothers (Mann–Whitney U test, P=0.797) (Figure 2C).

210 Determination of GIP in breast milk

211 We investigated the presence of gluten in breast milk by quantifying GIP using specific moAbs 212 (G12/A1). In the cohort of non-CD mothers without gluten restriction in their diet, 24% (23/96) of 213 breast milk samples contained detectable levels of GIP. There were no significant differences in the 214 GIP levels of whole milk and whey for these mothers. Urine samples tested positive for GIP in 90% 215 (86 out of 96) of volunteers within this cohort. The milk and urine samples were collected 216 consecutively over time, and our findings revealed that the concentrations of GIP in the milk were 217 significantly lower than those in the urine (average range according to the Mann–Whitney U test: 60.71 218 and 132.39, respectively) (P < 0.001) (Figure 3). However, 96% (22/23) of mothers who tested positive 219 in breast milk also had a GIP positive result in urine.

In the cohort of CD mothers, 82.6% (19/23) tested negative for GIP in breast milk. GIP was detected in only four breast milk samples and three urine samples from 23 participants, and one of the participants showed positive results for both samples. No significant differences were found between the GIP values of the milk and urine samples (P > 0.05).

These results suggest the presence of GIP across both biological fluids, albeit at varying levels, underscoring the importance of comprehensive assessment methods in elucidating GIP dynamics in lactating mothers with CD.

227

228 Longitudinal study

229 Kinetics of GIP secretion in breast milk

A parallel longitudinal descriptive study was conducted using a subgroup of 12 volunteers from the cohort of non-CD mothers. This study aimed to elucidate GIP kinetics in breast milk after maternal ingestion of gluten. For this purpose, all volunteers were instructed to complete a two-phase study: phase 1 on a controlled gluten-rich diet, and phase 2 on a strict GFD. GIP levels were quantified in breast milk and urine samples taken at various time points, from 0 to 96 h after gluten ingestion and at the onset of the GFD.

236 The results were GIP positive in 75% (9/12) of the participants in breast milk samples and 100% 237 (12/12) of the urine samples (Figure 4), considering at least one positive sample per participant. After 238 adopting a gluten-rich diet (0 h), 54.5% (6/11) of the volunteers tested positive for GIP in their breast 239 milk. At 3 and 6 h from the beginning of the GFD, GIP was detected in 33.3% (4/12) and 16.7% (2/12) 240 of the volunteers, respectively. In addition, we found positive GIP in breast milk on the following 241 hours: at 24, 48 and 72 h in 16.7% (2/12), 25% (3/12) and 8.3% (1/12) of the participants, respectively. 242 The means GIP values detected in breast milk were similar between 0 and 48 h, however, significant 243 differences were found after 72 h (P<0.05) (Figure 5A). No GIP was detected in breast milk after 72 h 244 in the volunteers studied. However, the period of GIP excretion in urine after the start of GFD is limited 245 to the first 24 h (100% of urine samples at 0h, 92% at 3 and 6 h, and 17% at 24 h) (Figure 5B).

246

247 **Discussion**

248

To our knowledge, this study represents the first instance of identifying immunogenic gluten peptides in breast milk samples. The presence of GIP in breast milk indicates that gluten is absorbed through the intestinal mucosa, enters the bloodstream, and is subsequently secreted by the mammary gland. The detection of measurable amounts of GIP in breast milk suggests that infants are exposed to

gluten antigens before their introduction into the diet, which could potentially impact CD developmentand other gluten-related disorders.

255 Our findings reveal that the secretion of GIP in breast milk exhibits dynamic and fluctuating 256 changes over time, likely influenced by various factors such as maternal diet, hormonal fluctuations, 257 and the feeding patterns of the infant, among others. This dynamic nature underscores the inherent 258 complexity involved in studying GIP in breast milk. Following a gluten-containing diet challenge and 259 the collection of multiple breast milk samples (ensuring at least one positive sample from each 260 participant), the percentage of GIP-positive participants was to 75%. The secretion kinetics extended 261 from 0 to 72 hours after the gluten-containing diet challenge and the commencement of the GFD. It is 262 important to note that a considerable degree of intra- and interindividual variation was observed in the 263 secretion of GIP, as previously reported for other food antigens [39-42].

264 Chirdo et al. [28] detected undegraded gliadins in all milk samples analyzed from lactating 265 mothers following a normal diet, using a polyclonal antibody. The concentrations of gliadins observed 266 exceeded those reported in our study to immunogenic gluten peptides. These variations may be 267 attributed to differences in the study populations, the identified epitopes, and the specificity of the 268 antibodies. The polyclonal antibodies are produced from a mixture of different immune cells, and they 269 may bind to unrelated proteins, causing cross-reactivity. This cross-reactivity can lead to false signals 270 or interference in assays. In contrast, our study has the advantage of detecting GIP using G12 and A1 271 moAbs, known for their reactivity with tandem epitopes contained in the major immunogenic peptides 272 associated with CD [36,43].

As expected, in the cohort of mothers with CD on a GFD, the majority of the breast milk samples (82.6%, 19/23) tested negative for GIP. Only four breast milk samples tested positive for GIP. Although the mothers with CD in our study followed a GFD, the possibility of dietary lapses cannot

rule out. A GFD is difficult to maintain, and adult patients with CD consume unsafe amounts of gluten
on average [44-46]. Therefore, these results may be attributed to possible transgressions in the GFD as
no food intake control was implemented for mothers with CD.

279 Understanding how other proteins manifest in breast milk is fundamental it provides crucial 280 insights into the composition of breast milk and its role in infant nutrition and development. In our 281 study, no significant differences were detected in the total protein levels in breast milk between non-282 CD and CD mothers. Thus, our findings suggest that a GFD does not influence variations in the levels 283 of this macronutrient in breast milk. These results agree with those of prior studies that have 284 demonstrated a remarkable consistency in the macronutrient composition of breast milk across 285 different populations despite potential variations in maternal nutritional status [47]. With respect to 286 food antigens, we also proved the transference of bovine casein into breast milk that represents one of 287 the most commonly secreted non-human proteins [21]. The levels of this protein in breast milk were 288 in the ng/mL range, similar to those of GIP and other food antigens [48]. No significant statistical 289 differences in bovine casein levels were observed between the non-CD and CD cohorts. This result 290 was expected, given that cow milk proteins are not only present in dairy products and their derivatives, 291 but are also widely incorporated into a myriad of manufactured items such as bread, cold cuts, sausages, frozen fish, sweeteners, preserves, and medicines. Additionally, numerous additives used in the food 292 293 industry are derived from milk [49].

The transfer of proteins from the maternal intestinal tract to the mammary gland is not yet well understood [24,48,50-52]. Additionally, food proteins secreted into the breast milk appear at highly variable concentrations at different time points following exposure and in different forms, either as free proteins or as components of immune complexes [24]. This makes it impossible to precisely predict the concentration at which food antigens/allergens will appear in breast milk and their impact on the immune response of the breast-fed children. For example, ovalbumin was detected in 68% of breast

300 milk samples following egg ingestion, while beta-lactoglobulin was found in 62.5% of lactating women 301 after consuming cow milk, exhibiting variable appearance and disappearance over a 15-hour sampling 302 period. Another study observed the presence of beta-lactoglobulin in breast milk up to 7 days after oral 303 intake of cow's milk [37]. Kinetic analysis of peanut protein transfer into breast milk revealed that 11 304 out of 23 mothers excreted peanut proteins, with 73% showing appearance within 1 hour of ingestion. 305 In this work, in a cohort of non-CD mothers, taking a single sample of breast milk and urine 306 consecutively over time, we have demonstrated that the percentage of GIP- positive milk samples was 307 significantly lower as compared to urine samples. The detection of GIP in the urine of 90% of non-CD 308 mothers implied that the vast majority of volunteers in this cohort consumed gluten; however, this 309 gluten intake was not reflected in breast milk (with only 24% breast milk being GIP positive). To 310 understand this differential excretion/secretion GIP pattern between urine and breast milk and the 311 excretion kinetics of gluten peptides in breast milk we designed a two-phase longitudinal trial: phase 312 1 involved a gluten-rich diet by menu planning, and phase 2 enforced a strict GFD. We measured GIP 313 levels in the breast milk at various time points, ranging from 0 to 96 h after gluten ingestion and at the 314 commencement of a GFD. The period of GIP excretion in urine after initiating the GFD was confined 315 to the initial 24 h, with 100% of the volunteers testing positive for GIP during this period. In contrast, 316 the period of GIP secretion in breast milk was extended to 72 h, with 75% of volunteers showing 317 positive GIP results. This result confirmed the differential kinetics of GIP in breast milk and urine 318 samples collected sequentially.

Gluten proteins are initially digested by the enzymes in the mother's intestinal tract. However, this digestion is often incomplete, leaving behind resistant peptides that can cross the intestinal barrier. It is probable that these peptides reach the mammary glands throughout the entire lactation process. We hypothesize that these peptides may undergo partial degradation before being secreted into the mammary glands, potentially extending the time of secretion. Consequently, the mammary gland could

324 serve as a reservoir for certain proteins, including gluten. This speculation arises from observations 325 that mothers who followed the same diet, with menu planning, exhibited fluctuating gluten secretion 326 and interindividual differences.

327 In this longitudinal trial, the children were breastfed during the milk sample collection period, 328 and this may limit the scope of our results. It should be noted that not all breast milk samples could be 329 collected within the designated 0 to 96 h timeframe, and GIP could have been secreted in some 330 uncollected milk samples. Pooled 24h milk samples are generally considered gold standards for collection; however, they are not possible if the mother wants to maintain normal breastfeeding 331 332 behaviors [42]. Furthermore, it is likely that the variations in the rate and concentration at which gluten 333 is secreted into breast milk can be attributed to the complexity and content of meals consumed before 334 or after gluten intake within our study group, and this could also contribute to the variations observed.

335 Our findings provide a conclusive demonstration of the presence of GIP in breast milk. Notable 336 aspects of this study include the analysis of breast milk samples and the sequential analysis of urine 337 samples using a specific assay designed for detecting GIP, coupled with the collection of multiple 338 samples over several days. We now have the molecular tool to further investigate whether and how 339 GIP are processed and secreted into breast milk. This investigation has raised important questions 340 about the role that these proteins may play in the development of the immune system of infants, 341 particularly considering that exposure to gluten in children occurs before the introduction of 342 complementary feeding, as was previously understood. Therefore, future studies are necessary to know 343 whether GIP act as sensitizing or tolerogenic agents in the immune system of breastfed babies.

344 Figures

345

	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4
Breakfast	GCD Toast	GCD Toast	GCD Toast	GFD Coffee / Fruit/Greek natural yogurt	GFD Coffee / Fruit/Greek natural yogurt	GFD Coffee / Fruit/Greek natural yogurt	GFD Coffee / Fruit/Greek natural yogurt
Lunch	GCD Pasta/Bread or Croutons/ lasagna	GCD Pasta/Bread or Croutons/ lasagna	GFD Ratatouille Fruit/Greek natural yogurt	GFD • Lentils • Fruit/Greek natural yogurt	GFD Grilled tuna Dressing with fish eggs Fruit/Greek natural yogurt	GFD Baked chicken Bonito in marinade Fruit/Greek natural yogurt	
Dinner	GCD Pizza/Sádwich/Whe at pancakes	GCD Pizza/Sádwich/Whe at pancakes	GFD Omelette Salad Fruit/Greek natural yogurt	GFD Octopus marinade Chicken Fruit/Greek natural yogurt	GFD Garlic chicken Fruit/Greek natural yogurt	GFD Grilled mushrooms Fruit/Greek natural yogurt	

в

A

DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4
		Collection of breast milk and urine samples: 1°) After breakfast 2°) 3 hours after the 1st sample 3°) 6 hours after the 1st sample	<u>Collection of breast</u> <u>milk. and urine</u> <u>samples:</u> 1 sample at 24 hours from the 1st sample	<u>Collection of breast</u> <u>milk and urine</u> <u>samples:</u> 1 sample at 48 hours from the 1st sample	<u>Collection of breast</u> <u>milk and urine</u> <u>samples:</u> 1 sample at 72 hours from the 1st sample	Collection of breast milk and urine samples: 1 sample at 96 hours from the 1st sample

346

Figure 1. Menu planning and sample collection planning. (A) Menu planning with foods rich in

348 gluten and menus with gluten-free. (B) Sample collection planning. GCD, gluten-containing diet; GFD,

349 gluten-free diet.

350





Figure 2. Total proteins and bovine caseins in breast milk. (A) Total protein content (mg/mL) in breast milk and whey (milk serum) of non-CD and CD mothers; (B) percentage of non-CD and CD mothers with casein in breast milk; (C) casein concentration in non-CD and CD mothers. Differences between groups were tested with a Wilcoxon signed-rank test in dependent groups and Mann–Whitney U test in independent groups. CD, celiac disease; LoQ, limit of quantification.





358 Figure 3. Detection and quantification of GIP in urine and breast milk of non-CD mothers and

359 **CD mothers**. n = 96 (non-CD mothers), n = 23 (CD mothers). The data points include 2 values per

360 volunteer. Differences in GIP levels in breast milk and urine between the 2 groups were tested with a

- 361 Mann–Whitney U test. CD, celiac disease; GIP, gluten immunogenic peptides; LoD, limit of detection;
- 362 LoQ, limit of quantification; ND, not detectable.



363

Figure 4. Kinetics of GIP secretion in breast milk and urine. Individual GIP excretion kinetics of
12 non-CD mothers on a GFD for over 96 h. The dashed orange lines correspond to breast milk
samples, and blue lines represent urine samples. GFD, gluten-free diet; GIP, gluten immunogenic
peptides; LoQ, limit of quantification; LoD, limit of detection.



368

369 Figure 5. Comparison of GIP levels in breast milk and urine of 12 non-CD mothers on a GFD

370 for over 96 h after gluten ingestion. (A) GIP secretion in breast milk; (B) GIP excretion in urine.

371 Comparative analysis via the McNemar test of GIP levels before and after consumption of gluten. GIP,

372 gluten immunogenic peptides; LoD, limit of detection.

373

374 Conflict of Interest

375 The authors declare that the research was conducted in sthe absence of any commercial or financial

376 relationships that could be construed as a potential conflict of interest.

377

Author Contributions
Conceptualization, Á.RC., V.S., and I.C.; data curation, Á.RC and V.S.; formal analysis, Á.RC
and V.S; investigation, Á.RC., V.S., M.d.L.M., C.CR., C.S. and I.C.; methodology, Á.RC., V.S.,
and I.C; resources, Á.RC., V.S., and I.C; writing-original draft, Á.RC., V.S., C.S. and I.C;
writing-review and editing, Á.RC., V.S., M.d.L.M., C.CR., C.S. and I.C. All authors have read
and agreed to the published version of the manuscript.
Funding
Funding This work was supported by grant from Consejería de Economía y Conocimiento, Junta de Andalucía
Funding This work was supported by grant from Consejería de Economía y Conocimiento, Junta de Andalucía (project P18-RT-3004) PAIDI 2018.
Funding This work was supported by grant from Consejería de Economía y Conocimiento, Junta de Andalucía (project P18-RT-3004) PAIDI 2018.
Funding This work was supported by grant from Consejería de Economía y Conocimiento, Junta de Andalucía (project P18-RT-3004) PAIDI 2018.
Funding This work was supported by grant from Consejería de Economía y Conocimiento, Junta de Andalucía (project P18-RT-3004) PAIDI 2018. Acknowledgments We would like to thank the Federation of Celiac Associations of Spain (FACE) and the Provincial

393

392

394 Reference

volunteer mothers who enrolled in the study.

- 395 1. Al-Toma, A., Volta, U., Auricchio, R., Castillejo, G., Sanders, D. S., Cellier, C., et al (2019). European 396 Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related 397 disorders. United European Gastroenterol. J. 7(5):583-613. doi: 10.1177/2050640619844125.
- 398 2. Besser, HA., Khosla, C (2023). Celiac disease: mechanisms and emerging therapeutics. Trends 399 Pharmacol. Sci. 44(12):949-962. doi: 10.1016/j.tips.2023.09.006.
- 400 3. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al (2019). Celiac disease: a 401 comprehensive current review. BMC Med. 17(1):142. doi: 10.1186/s12916-019-1380-z.

- 402
 4. King, JA., Jeong, J., Underwood, FE., Quan, J., Panaccione, N., Windsor, JW., et al (2020). Incidence
 403
 404
 404
 405
 404
 404
 404
 404
 405
 404
 404
 404
 404
 404
 404
 405
 405
 406
 406
 407
 407
 407
 408
 409
 409
 409
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 <li
- 5. Singh, P., Arora, A., Strand, TA., Leffler, DA., Catassi, C., Green, PH., et al (2018). Global prevalence
 of celiac disease: systematic review and meta-analysis. Clinical gastroenterology and hepatology: the
 official clinical practice journal of the American Gastroenterological Association, 16(6), 823–836.e2.
 https://doi.org/10.1016/j.cgh.2017.06.037.
- 409
 6. Mardini, HE., Westgate, P., Grigorian, AY (2015). Racial differences in the prevalence of celiac disease
 410
 411 in the us population: national health and nutrition examination survey (NHANES) 2009-2012. Dig. Dis.
 411 Sci. 60(6):1738-1742. doi: 10.1007/s10620-014-3514-7.
- 412
 7. Lebwohl, B., Green, PHR., Söderling, J., Roelstraete, B., Ludvigsson, JF (2020). Association between
 413
 414
 414
 414
 10.1001/jama.2020.1943.
- 415 8. Ludvigsson, JF., Murray, JA (2019). Epidemiology of celiac disease. Gastroenterol. Clin. North Am.
 416 48(1):1-18. doi:10.1016/j.gtc.2018.09.004.
- 417 9. Lebwohl, B., Rubio-Tapia, A (2021). Epidemiology, presentation, and diagnosis of celiac disease.
 418 Gastroenterology. 160(1):63-75. doi:10.1053/j.gastro.2020.06.098.
- Villamil, E., Rodríguez-Camejo, C., Puyol, A., Fazio, L., Colistro, V., Hernández, A (2021). Immune
 profiling of breast milk from mothers with treated celiac disease. Pediatr. Res. 89(3):488-495.
 doi:10.1038/s41390-020-0901-y.
- 422 11. Akobeng, AK., Ramanan, AV., Buchan, I., Heller, RF (2006). Effect of breast feeding on risk of coeliac
 423 disease: a systematic review and meta-analysis of observational studies. Arch. Dis. Child. 91(1):39-43.
 424 doi:10.1136/adc.2005.082016.
- 425 12. Aronsson, CA., Agardh, D (2023). Intervention strategies in early childhood to prevent celiac disease426 a mini-review. Front. Immunol. 14:1106564. doi:10.3389/fimmu.2023.1106564.
- 427 13. Lionetti, E., Castellaneta, S., Francavilla, R., Pulvirenti, A., Tonutti, E., Amarri, S., et al (2014).
 428 Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl. J. Med.
 429 371(14):1295-1303. doi:10.1056/NEJMoa1400697.
- 430 14. Vriezinga, SL., Auricchio, R., Bravi, E., Castillejo, G., Chmielewska, A., Crespo-Escobar, P., et al
 431 (2014). Randomized feeding intervention in infants at high risk for celiac disease. N. Engl. J. Med.
 432 371(14):1304-15. doi:10.1056/NEJMoa1404172.
- 433 15. Silano, M., Agostoni, C., Sanz, Y., Guandalini, S (2016). Infant feeding and risk of developing celiac
 434 disease: a systematic review. BMJ Open. 6(1):e009163. doi:10.1136/bmjopen-2015-009163.
- 435 16. Borba, V., Sharif, K., Shoenfeld, Y (2018). Breastfeeding and autoimmunity: Programing health from
 436 the beginning. Am. J. Reprod. Immunol. 79(1). doi:10.1111/aji.12778.

- 437 17. van den Elsen, LWJ., Garssen, J., Burcelin, R., Verhasselt, V (2019). shaping the gut microbiota by
 438 breastfeeding: the gateway to allergy prevention? Front. Pediatr. 7:47. doi:10.3389/fped.2019.00047.
- 439 18. Samuel, TM., Zhou, Q., Giuffrida, F., Munblit, D., Verhasselt, V., Thakkar, SK (2020). Nutritional and
 440 Non-nutritional Composition of Human Milk Is Modulated by Maternal, Infant, and Methodological
 441 Factors, Front. Nutr. 7:576133. doi: 10.3389/fnut.2020.576133.
- 442 19. Nuzzi, G., Di Cicco, ME., Peroni, DG (2021). Breastfeeding and allergic diseases: What's new?
 443 Children (Basel). 8(5):330. doi:10.3390/children8050330.
- 444 20. Kosmeri, C., Rallis, D., Kostara, M., Siomou, E., Tsabouri, S (2022). Characteristics of exogenous
 445 allergen in breast milk and their impact on oral tolerance induction. Front. Pediatr. 10:830718.
 446 doi:10.3389/fped.2022.830718.
- 447 21. Franco, C., Fente, C., Sánchez, C., Lamas, A., Cepeda, A., Leis, R., et al (2022). Cow's milk antigens
 448 content in human milk: a scoping review. Foods. 11(12):1783. doi:10.3390/foods11121783.
- 22. Bernard, H., Ah-Leung, S., Drumare, MF., Feraudet-Tarisse, C., Verhasselt, V., Wal, JM., et al (2014).
 Peanut allergens are rapidly transferred in human breast milk and can prevent sensitization in mice.
 Allergy. 69(7):888-897. doi:10.1111/all.12411.
- 452 23. Vadas, P., Wai, Y., Burks, W., Perelman, B (2001). Detection of peanut allergens in breast milk of
 453 lactating women. JAMA. 285(13):1746-1748. doi:10.1001/jama.285.13.1746.
- 454 24. Macchiaverni, P., Tulic, MK., Verhasselt, V (2013). "Antigens in breast milk: possible impact on
 455 immune system education". In Handbook of dietary and nutritional aspects of human breast milk.
 456 Leiden, The Netherlands: Wageningen Academic. 5:447-460. doi: 10.3920/978-90-8686-764-6_25.
- 457 25. Palmer, DJ., Gold, MS., Makrides, M (2005). Effect of cooked and raw egg consumption on ovalbumin
 458 content of human milk: a randomized, double-blind, cross-over trial. Clin Exp Allergy. 35(2):173-178.
 459 doi:10.1111/j.1365-2222.2005.02170.x
- 460 26. Fukushima, Y., Kawata, Y., Onda, T., Kitagawa, M (1997). Consumption of cow milk and egg by
 461 lactating women and the presence of beta-lactoglobulin and ovalbumin in breast milk. Am. J. Clin. Nutr.
 462 65(1):30-35. doi:10.1093/ajcn/65.1.30.
- 27. Troncone, R., Scarcella, A., Donatiello, A., Cannataro, P., Tarabuso, A., Auricchio, S (1987). Passage
 of gliadin into human breast milk. Acta Paediatr. Scand. 76(3):453-456. doi:10.1111/j.16512227.1987.tb10498.x
- 28. Chirdo, FG., Rumbo, M., Añón, MC., Fossati, CA (1998). Presence of high levels of non-degraded
 gliadin in breast milk from healthy mothers. Scand. J. Gastroenterol. 33(11):1186-1192.
 doi:10.1080/00365529850172557.
- 469 29. Shan, L., Molberg, Ø., Parrot, I., Hausch, F., Filiz, F., Gray, GM., et al (2002). Structural basis for gluten
 470 intolerance in celiac sprue. Science. 297(5590):2275-2279. doi:10.1126/science.1074129

- 471 30. Heyman, M., Abed, J., Lebreton, C., Cerf-Bensussan, N (2012). Intestinal permeability in coeliac
 472 disease: insight into mechanisms and relevance to pathogenesis. Gut. 61(9):1355-1364.
 473 doi:10.1136/gutjnl-2011-300327.
- 474 31. Palanski, BA., Weng, N., Zhang, L., Hilmer, AJ., Fall, LA., Swaminathan, K., et al (2022). An efficient
 475 urine peptidomics workflow identifies chemically defined dietary gluten peptides from patients with
 476 celiac disease. Nature communications, 13(1), 888. doi:10.1038/s41467-022-28353-1.
- 477 32. Comino, I., Real, A., Vivas, S., Síglez, MÁ., Caminero, A., Nistal, E., et al (2012). Monitoring of gluten478 free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces.
 479 Am. J. Clin. Nutr. 95(3):670-677. doi:10.3945/ajcn.111.026708.
- 480 33. Comino, I., Fernández-Bañares, F., Esteve, M., Ortigosa, L., Castillejo, G., Fombuena, B., et al (2016). 481 Fecal gluten peptides reveal limitations of serological tests and food questionnaires for monitoring 482 gluten-free diet in celiac disease patients. Am. J. Gastroenterol. 111:1456-65. 483 doi:10.1038/ajg.2017.110.
- 484 34. Comino, I., Segura, V., Ortigosa, L., Espín, B., Castillejo, G., Garrote, J.A., et al (2019). Prospective
 485 longitudinal study: Use of faecal gluten immunogenic peptides to monitor children diagnosed with
 486 coeliac disease during transition to a gluten-free diet. Aliment. Pharmacol. Ther. 49:1484–1492.
 487 doi:10.1111/apt.15277.
- 488 35. Moreno, MdeL., Cebolla, Á., Muñoz-Suano, A., Carrillo-Carrion, C., Comino, I., Pizarro, Á., et al
 489 (2017). Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals
 490 transgressions in the gluten-free diet and incomplete mucosal healing. Gut. 66:250-257.
 491 doi:10.1136/gutjnl-2015-310148
- 36. Ruiz-Carnicer, Á., Garzón-Benavides, M., Fombuena, B., Segura, V., García-Fernández, F., SobrinoRodríguez, S., et al (2020). Negative predictive value of the repeated absence of gluten immunogenic
 peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for followup in celiac disease. Am. J. Clin. Nutrition. 112(5), 1240–1251. doi:10.1093/ajcn/nqaa188.
- 496 37. Picariello, G., De Cicco, M., Nocerino, R., Paparo, L., Mamone, G., Addeo, F., et al (2019). Excretion
 497 of dietary cow's milk derived peptides into breast milk. Front. Nutr. 6:25. doi:10.3389/fnut.2019.00025.
- 38. Dekker, P. M., Boeren, S., Wijga, A. H., Koppelman, G. H., Vervoort, J. J. M., & Hettinga, K. A. (2020).
 Maternal Allergy and the Presence of Nonhuman Proteinaceous Molecules in Human Milk. Nutrients,
 12(4), 1169. https://doi.org/10.3390/nu12041169.
- 39. Daly, SE., Di Rosso, A., Owens, RA., Hartmann, PE (1993). Degree of breast emptying explains
 changes in the fat content, but not fatty acid composition, of human milk. Exp. Physiol. 78(6):741-755.
 doi:10.1113/expphysiol.1993.sp003722.
- 40. Ruel, MT., Dewey, KG., Martínez, C., Flores, R., Brown, KH (1997). Validation of single daytime
 samples of human milk to estimate the 24-h concentration of lipids in urban Guatemalan mothers. Am.
 J. Clin. Nutr. 65(2):439-44.

- 41. Kent, JC., Mitoulas, LR., Cregan, MD., Ramsay, DT., Doherty, DA., Hartmann, PE (2006). Volume
 and frequency of breastfeedings and fat content of breast milk throughout the day. Pediatrics.
 117(3):e387-395. doi:10.1542/peds.2005-1417
- 42. Keikha, M., Bahreynian, M., Saleki, M., Kelishadi, R (2017). Macro- and micronutrients of human milk
 composition: are they related to maternal diet? A comprehensive systematic review. Breastfeed Med.
 12(9):517-527. doi:10.1089/bfm.2017.0048
- 43. Morón, B., Bethune, MT., Comino, I., Manyani, H., Ferragud, M., López, MC., et al Toward the
 assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main
 immunogenic gluten peptide. PLoS One. 2008;3(5):e2294.
- 44. Silvester, JA., Comino, I., Kelly, CP., Sousa, C., Duerksen, DR., DOGGIE BAG Study Group. (2020).
 Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten.
 Gastroenterology, 158(5):1497–1499.e1. doi:10.1053/j.gastro.2019.12.016.
- 519 45. Silvester, JA., Comino, I., Rigaux, LN., Segura, V., Green, KH., Cebolla, A., et al (2020). Exposure
 520 sources, amounts and time course of gluten ingestion and excretion in patients with coeliac disease on
 521 a gluten-free diet. Aliment. Pharmacol. Ther. 52(9):1469–1479. doi:10.1111/apt.16075.
- 46. Wieser, H., Ruiz-Carnicer, Á., Segura, V., Comino, I., Sousa, C. (2021). Challenges of Monitoring the
 gluten-free diet adherence in the management and follow-up of patients with celiac disease. Nutrients.
 13(7):2274. doi:10.3390/nu13072274
- 525 47. Fields, DA., Demerath, EW (2013). Human milk composition: nutrients and bioactive factors. Pediatr.
 526 Clin. North Am. 60(1):49-74.
- 48. Schocker, F., Jappe, U (2022). Breastfeeding: maternally transferred allergens in breast milk: protective
 or sensitizing? Mol. Nutr. Food Res. 66(15):e2200066. doi:10.1002/mnfr.202200066.
- 49. Al-Beltagi, M., Saeed, NK., Bediwy, AS., Elbeltagi, R (2022). Cow's milk-induced gastrointestinal
 disorders: From infancy to adulthood. World J. Clin. Pediatr. 11(6):437-454.
 doi:10.5409/wjcp.v11.i6.437.
- 50. Benn, CS., Böttcher, MF., Pedersen, BV., Filteau, SM., Duchén, K (2004). Permeabilidad paracelular
 epitelial mamaria en madres atópicas y no atópicas versus atopia infantil. Pediatra. Inmunol. alérgico.
 15:123-126.
- 535 51. Monjes, J., Neville, MC (2004). Transcitosis de albúmina a través del epitelio de la glándula mamaria
 536 del ratón lactante. J. Physiol. 560:267–280.
- 537 52. Pastor-Vargas, C., Maroto, AS., Díaz-Perales, A., Villaba, M., Diaz, NC., Vivanco, F, et al (2015).
 538 Sensitive detection of major food allergens in breast milk: first gateway for allergenic contact during
 539 breastfeeding. Allergy. 70(8):1024-1027. doi:10.1111/all.12646.
- 540
- 541